BG & TMZ Therapy of Glioblastoma Multiforme

Inclusion Criteria: * Patients with histologically confirmed, newly diagnosed, supratentorial GBM who have undergone gross total tumor resections or near gross total resection (resection of \>90% of enhancing tumor demonstrated by MRI) are eligible up to their third post-operative week. Patients with infratentorial disease, multifocal or leptomeningeal disease will be excluded. In general, patients will not have \> 1 cm residual measurable or evaluable disease after surgical tumor resection. * ECOG performance status 0-2 or Karnofsky ≥ 70. * Patients must have received no myelosuppressive chemotherapy prior to the diagnosis of GBM. * Life expectancy of at least 12 weeks. * Adequate hematologic (ANC ≥ 1,000/mm3, platelets ≥ 100,000/mm3, Hgb ≥ 9.5) , hepatic (Bilirubin ≤ 2.0 mg/dl, AST and ALT less than or equal to 3 times upper limit of normal, prothrombin time \<1.2 times normal), and renal (Serum creatinine ≤ 2.0 mg/dl or Creatinine Clearance ≥ 60mL/min/1.73 m2 for subjects with serum creatinine levels above institutional normal) . These tests will be repeated within 2 weeks of treatment with BG and TMZ, and must meet the same criteria. * EKG without evidence of acute cardiac disease. * Left ventricular ejection fraction (LVEF) ≥ 40 * Post-operative steroids are tapered to ≤ 24 mg decadron/d * Patients of child-bearing potential must be using single barrier contraception * Willingness and ability to provide informed consent. * Patient must have all sutures removed prior to …